<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05046808</url>
  </required_header>
  <id_info>
    <org_study_id>FMTN-I-110</org_study_id>
    <nct_id>NCT05046808</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Study of Famitinib Malate Capsules in Healthy Subjects</brief_title>
  <official_title>A Single-center, Randomized, Open-label Pharmacokinetic Study of Famitinib Malate Capsules in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, open-label study to compare the pharmacokinetic profiles&#xD;
      of Famitinib and its metabolite SHR116637 at different doses/specifications.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 23, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) for Famitinib after Single dose</measure>
    <time_frame>from Day 1 to Day 9 after the first dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC0-t) for Famitinib after Single dose</measure>
    <time_frame>from Day 1 to Day 9 after the first dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC0-∞) for Famitinib after Single dose</measure>
    <time_frame>from Day 1 to Day 9 after the first dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum observed plasma concentration (Tmax) for Famitinib after Single dose</measure>
    <time_frame>from Day 1 to Day 9 after the first dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination half-life (T1/2) for Famitinib after Single dose</measure>
    <time_frame>from Day 1 to Day 9 after the first dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent oral clearance (CL/F) for Famitinib after Single dose</measure>
    <time_frame>from Day 1 to Day 9 after the first dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) Famitinib after Single dose</measure>
    <time_frame>from Day1 to Day9 after the first dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) for SHR116637 after Single dose</measure>
    <time_frame>from Day 1 to Day 9 after the first dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC0-t) for SHR116637 after Single dose</measure>
    <time_frame>from Day 1 to Day 9 after the first dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC0-∞) for SHR116637 after Single dose</measure>
    <time_frame>from Day 1 to Day 9 after the first dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum observed plasma concentration (Tmax) for SHR116637 after Single dose</measure>
    <time_frame>from Day 1 to Day 9 after the first dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to elimination half-life (T1/2) for SHR116637 after Single dose</measure>
    <time_frame>from Day 1 to Day 9 after the first dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent oral clearance (CL/F) for SHR116637 after Single dose</measure>
    <time_frame>from Day 1 to Day 9 after the first dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) SHR116637 after Single dose</measure>
    <time_frame>from Day 1 to Day 9 after the first dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events and severity of adverse events</measure>
    <time_frame>from Day 1 to Day 16 after the first dose</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Famitinib Malate Capsules 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Famitinib Malate Capsules 15mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Famitinib Malate Capsules 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Famitinib Malate Capsules 10mg*2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Famitinib Malate Capsules 25mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famitinib Malate Capsules</intervention_name>
    <description>Famitinib Malate Capsules 10mg single dose</description>
    <arm_group_label>Famitinib Malate Capsules 10mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famitinib Malate Capsules</intervention_name>
    <description>Famitinib Malate Capsules 15mg single dose</description>
    <arm_group_label>Famitinib Malate Capsules 15mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famitinib Malate Capsules</intervention_name>
    <description>Famitinib Malate Capsules 20mg single dose</description>
    <arm_group_label>Famitinib Malate Capsules 20mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famitinib Malate Capsules</intervention_name>
    <description>Famitinib Malate Capsules 10mg*2 single dose</description>
    <arm_group_label>Famitinib Malate Capsules 10mg*2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famitinib Malate Capsules</intervention_name>
    <description>Famitinib Malate Capsules 25mg single dose</description>
    <arm_group_label>Famitinib Malate Capsules 25mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Gender: healthy male and female subjects.&#xD;
&#xD;
          2. Age: 18 years old and above (including 18 years old).&#xD;
&#xD;
          3. Weight: male subjects should not be less than 50.0kg, female subjects should not be&#xD;
             less than 45.0kg, body mass index [BMI=weight (kg)/height2 (m2)] is 19.0 to 26.0kg/m2&#xD;
             (including boundary values).&#xD;
&#xD;
          4. Subjects with fertility and their partners have no fertility plan and voluntarily take&#xD;
             medically approved high-efficiency contraception methods (see appendix 1 for details),&#xD;
             and no plan to donate eggs or sperm within 28 weeks after signing the informed&#xD;
             consent. Women with childbearing potential must have a negative serum pregnancy test&#xD;
             within 24 hours before taking the study drug for the first time.&#xD;
&#xD;
          5. Subjects must give informed consent to this study before the experiment, and&#xD;
             voluntarily sign a written informed consent form.&#xD;
&#xD;
          6. The subject can communicate well with the researcher and can complete the research in&#xD;
             accordance with the research regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those who are allergic to the active ingredients of the preparation and related&#xD;
             compounds and any excipients or are allergic to two or more drugs (or food).&#xD;
&#xD;
          2. Those who cannot follow a unified diet (such as intolerance to standard meals, etc.).&#xD;
&#xD;
          3. Those who cannot tolerate venepuncture, and those who have a history of fainting&#xD;
             needles and bleeding.&#xD;
&#xD;
          4. There is a history of cardiovascular (such as hypertension), liver, kidney (such as&#xD;
             chronic kidney disease), endocrine, blood system, respiratory system, malignant&#xD;
             tumour, mental abnormality, severe infection, etc. or the existing above diseases that&#xD;
             the researcher judges to be clinically significant.&#xD;
&#xD;
          5. Chronic or active gastrointestinal diseases such as esophagitis, gastritis, gastric&#xD;
             ulcer, enteritis, gastrointestinal bleeding, gastroesophageal reflux disease,&#xD;
             gastrointestinal obstruction, oesophageal varices, or gastrointestinal surgery (part&#xD;
             of the digestive tract resection, cholecystectomy), etc., and the investigator&#xD;
             believes that there is still clinical significance.&#xD;
&#xD;
          6. During the screening period, there are serious gastrointestinal symptoms (such as&#xD;
             nausea, vomiting, stomach pain, abdominal pain, diarrheal, abdominal discomfort,&#xD;
             abdominal distension, etc.), and the investigator believes that it is currently&#xD;
             clinically meaningful.&#xD;
&#xD;
          7. Patients with upper respiratory tract infection during the screening period, and the&#xD;
             investigator believes that it is currently clinically significant.&#xD;
&#xD;
          8. Those who have undergone major surgery within 6 months before screening, or who plan&#xD;
             to undergo surgery during the study period, and those who have undergone surgery that&#xD;
             will affect drug absorption, distribution, metabolism, and excretion (except for&#xD;
             appendicitis surgery).&#xD;
&#xD;
          9. During the screening period, physical examination, vital signs, 12-lead&#xD;
             electrocardiogram, chest radiograph, abdominal ultrasound, blood routine, blood&#xD;
             biochemistry, urine routine, blood coagulation and thyroid function (FT3, FT4, TSH)&#xD;
             abnormalities, the investigator judged that the abnormalities have clinical&#xD;
             significance.&#xD;
&#xD;
         10. Abnormal test results of hepatitis B surface antigen, hepatitis C virus antibody,&#xD;
             Treponema pallidum antibody or human immunodeficiency virus antibody have clinical&#xD;
             significance.&#xD;
&#xD;
         11. Those who drank excessive amounts of tea, coffee, or caffeinated beverages (more than&#xD;
             8 cups a day, 1 cup = 200 mL) within 3 months before screening; or consumed any food&#xD;
             or beverages containing caffeine within 48 hours before the first administration of&#xD;
             the study drug (Such as coffee, strong tea, chocolate, etc.).&#xD;
&#xD;
         12. Those who have consumed any beverages or foods that are rich in xanthine or grapefruit&#xD;
             ingredients or other beverages or foods that affect the absorption, distribution,&#xD;
             metabolism, and excretion of the drug within 48 hours before the first administration&#xD;
             of the study drug.&#xD;
&#xD;
         13. Any drug that interacts with this drug has been used within 4 weeks before screening&#xD;
             (see appendix 3).&#xD;
&#xD;
         14. Those who have used long-acting estrogen or progestin injections or implants within 6&#xD;
             months before the test; those who have used short-acting contraceptives within 30 days&#xD;
             before the test.&#xD;
&#xD;
         15. Those who have used any prescription drugs, over-the-counter drugs, Chinese herbal&#xD;
             medicines, or health care products in the 14 days before the first administration of&#xD;
             the study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 8, 2021</study_first_submitted>
  <study_first_submitted_qc>September 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>October 9, 2021</last_update_submitted>
  <last_update_submitted_qc>October 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

